Skip to main content
. Author manuscript; available in PMC: 2015 Aug 1.
Published in final edited form as: Kidney Int. 2014 Jul 23;87(2):409–416. doi: 10.1038/ki.2014.261

Figure 2. Rituximab induction reduces donor-specific (DSA) and non-DSA HLA antibody strength and incidence of rebound post-transplantation.

Figure 2

The change in pre-treatment MFI and peak post-transplant MFI for donor-specific (DSA) and non-DSA HLA antibodies were compared between patients transplanted with or without rituximab induction. Values plotted above dotted line represent a post-transplant antibody rebound above pre-treatment levels. The mean MFI change for DSA (−2505 versus −292, p= 0.006) and for non-DSA HLA antibodies (−309 versus +1938, p= 0.0006) are denoted by solid lines and were statistically lower in patients transplanted with rituximab induction.